Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited second quarter 2026 financial and operating results.

• Global net revenue is expected to be approximately €7.7 million in the second quarter of 2026, which reflects 21% sequential growth over the first quarter of 2026
• U.S. net revenue is expected to be approximately €5.2 million in the second quarter of 2026, which reflects 22% sequential growth over the first quarter of 2026

The Company continues to expect global net revenue for the full year 2026 to be in the range of €36 million to €40 million. 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.